80 results about "Peripheral blood cell" patented technology

The invention relates to a medical image processing and recognition technology, in particular to a blood cell automatic detection method based on a grading strategy, which comprises the following steps: acquiring a blood cell image set with a label, performing data enhancement on the data set to obtain a first training data set, and selecting a minority class of samples in the first training data set as a second training data set; training a secondary classification network by using the second training data set; constructing an improved YOLOv8 target detection algorithm model, and if the category output by a detection head in the YOLOv8 target detection algorithm model is not a minority category, directly outputting a detection result; and if the category of the single cell image output by the detection head is a minority category, inputting the single cell image into a pre-trained secondary classification network, and obtaining a final category probability by combining the confidence of the secondary classification network with an improved YOLOv8 target detection algorithm model. The method can improve the detection accuracy and the detection rate, and is suitable for the scene of peripheral blood cell detection.

The invention discloses an application of CD4 + CD8 + double-positive T cells in improvement of poor immune reconstitution of HIV (human immunodeficiency virus) infected patients, and relates to the technical field of biological pharmacy, in particular to the application of preparation of the CD4 + CD8 + double-positive T cells in the poor immune reconstitution of the HIV infected patients. The number of peripheral blood CD4 + T cells of HIV infected patients is increased, the immune system of the patients is improved, and the probability of possible opportunity infection and other related diseases of the patients is reduced, so that the morbidity and mortality of the patients are reduced.

Disclosed are methods for producing a population of autologous engineered cells to be reinfused into a subject comprising extracorporeally transfecting an internal payload into a population of target cells from a sample obtained from the subject by incubating the population of cells with a lipid nanoparticle (LNP) and / or targeting lipid nanoparticle (tLNP) in an incubation component of an extracorporeal system for no more than 6 hours.

The utility model discloses a portable peripheral blood cell counter which comprises a glass slide and a cover glass, and the cover glass is positioned at the upper end of the glass slide; the carrying and placing frame is arranged at the lower end of the glass slide, a rectangular placing open groove is formed in the upper end face of the carrying and placing frame, L-shaped positioning pieces are fixed to the four corners of the upper end of the rectangular placing open groove in the carrying and placing frame, and the glass slide is located in the rectangular placing open groove and clamped among the four L-shaped positioning pieces; the semicircular through groove is formed in the middle of the front end face and the rear end face of the carrying and placing frame, and the semicircular through groove vertically penetrates through the carrying and placing frame. According to the blood cell counter, external protection of glass slides and cover glass is achieved, the effect that each group of cover glass and glass slides are separated is achieved, and therefore the problems that a main body of an existing blood cell counter used for counting is made of glass slides and cover glass, the glass slides and the cover glass are prone to colliding with each other during placement, damage can occur, and peripheral blood cell counting is affected are effectively solved.

Methods, compositions of matter and protocols for generation of dedifferentiated cells possessing pluripotent or multipotent ability. Methods include extracting cells with proclivity for dedifferentiation from peripheral blood, culturing said cells in a media to provide stable expansion of said cells, and subsequently applying a multistep dedifferentiation protocol to achieve a population of pluripotent and / or multipotent cells. Peripheral blood cells are enriched for cells expressing Vasa and / or Dazl, and / or Stella and expanded under conditions to support proliferation without loss of these markers. Subsequently cells are treated with dedifferentiation cocktails in a multi-step manner in order to generate pluripotent stem cells. Said pluripotent stem cells are capable of generating multi-lineage cells as well as express characteristic markers of pluripotency such as OCT4 and NANOG.

The invention provides a new bunyavirus neutralizing antibody screening method based on single cell BCR sequencing. The new bunyavirus neutralizing antibody screening method comprises the following steps: S1, collecting peripheral blood B cells of acute stage and recovery stage patients and healthy volunteers of new bunyavirus infected persons; s2, carrying out CD19 < + > CD38 < + > CD138 < + > magnetic bead separation to obtain a single-cell suspension; s3, constructing a single cell transcriptome and a BCR library, separating single cells by using a microfluidic system, and performing high-throughput sequencing; s4, analyzing a B cell subset, a BCR cloning amplification mode and a VJ gene pair enrichment characteristic through bioinformatics analysis; and S5, screening a specific BCR clone type related to the severity of the disease as a neutralizing antibody candidate target. The method provided by the invention provides powerful support for immune monitoring and vaccine design of new bunyavirus infection, and is expected to provide new strategies and methods for clinical treatment and prevention.

The invention discloses a Wright staining peripheral blood cell accurate identification system and method based on intelligent microscopic imaging and multi-modal fusion deep learning, belongs to the crossing field of medical examination and artificial intelligence, and is suitable for cell morphology analysis under a 10 * 40-time microscope. The core scheme comprises the following steps: standardized slide preparation and dyeing (the slide pushing angle is 25 + / -2 degrees, the pH is 6.8 + / -0.2, and color sensing dynamic regulation is performed); intelligent imaging (focusing formula and color normalization; the method comprises the following steps of (1) data processing, (2) data processing, (3) data processing, (4) data processing, (5) data processing, (6) data processing, (7) data processing, (8) data processing, (7) data processing, (8) data processing, (8) data processing, (8) data processing, (8) data processing, (8) data processing and (8) data processing.

To provide recombinant polyclonal proteins and use methods thereof.SOLUTION: Provided herein is a composition comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells or plasmablasts. Methods for using the RPPs are also provided. The RPPs are recombinant, and their sequences are derived from peripheral blood plasma cells or plasmablasts. The peripheral blood plasma cells or plasmablasts are mobilized by, e.g., a vaccine administered to a donor, and the peripheral blood plasma cells or plasmablasts are specifically separated from other peripheral blood cells. The peripheral blood cells can come from any mammal, for example a mouse, a rat, a human, a monkey, a horse, or a cow.SELECTED DRAWING: None

The invention discloses a pig whole sperm membrane protein antigen specific nano antibody library construction method which comprises the following steps: S1, immunizing alpaca with pig whole sperms, and separating peripheral blood cells after immunization; s2, RNA in peripheral blood cells is extracted, cDNA is obtained through reverse transcription, and a VHH coding sequence of an antibody is amplified; s3, cloning the amplified VHH coding sequence to a bacteriophage plasmid vector to prepare a recombinant bacteriophage vector; s4, transforming the recombinant bacteriophage vector into escherichia coli and carrying out enlarged culture to obtain a bacteriophage display library; and S5, performing panning on the phage display library for a plurality of times by using the pig X / Y sperms, and constructing the pig single sex sperm specific nano antibody library. According to the method, the pig whole sperm is adopted as an immunogen for immunizing alpaca for the first time, the capacity of the constructed antibody library reaches 3.4 * 10 < 8 > pfu, the abundance of the antibody library is higher, the coverage degree of whole sperm antigens is higher, and the variety is more complete, so that the capture success rate of the pig sex control specific antibody is increased, and a foundation is laid for industrial application of the pig sperm specific antibody.

The invention provides an ischemic stroke auxiliary diagnosis system based on a peripheral blood T cell single cell transcriptome and application thereof, and the auxiliary diagnosis system comprises a peripheral blood mononuclear cell acquisition module, a single cell RNA sequencing module, a data processing module, a data analysis module and a result discrimination module. With a coding gene of a protein molecule significantly related to the occurrence of ischemic stroke as a target gene, a data processing module obtains the expression level of the target gene in each T cell; the data analysis module obtains a risk score of each T cell of the subject by using a built-in single cell risk scoring model, and weights the risk scores of all the T cells through distributed perception identification to obtain an individual risk score of the subject; and the result judgment module is used for classifying the subjects into ischemic stroke negative and ischemic stroke positive according to the individualized risk scores of the subjects. The auxiliary diagnosis system disclosed by the invention is high in ischemic stroke discrimination capability, and high in sensitivity and specificity.

The invention discloses a biomarker for early warning or diagnosis of early-stage PD (Parkinson's Disease) and application thereof, belongs to the technical field of biological medicines, and proposes that the level of peripheral blood P-LCK cells in a blood sample is taken as the biomarker for the first time, and the biomarker has extremely high accuracy, specificity and sensitivity for early warning or diagnosis of early-stage PD.

The invention discloses application of 5 beta-cholanic acid (5 beta-CA) in enhancement of NK cell functions and preparation of antiviral drugs. The NK cell function of a chronic hepatitis B (CHB) patient is depleted, it is found that the intracellular 5beta-CA level is reduced by screening differential metabolites of peripheral blood NK cells of the CHB patient, and the NK cell function of the CHB patient can be enhanced by exogenous supplementation of 5beta-CA; the function of NK cells of HBV persistently infected mice can be enhanced, and the level of virology indexes such as serum HBV related antigens and the like can be reduced. Specifically, the 5beta-CA enhances the NK cell function by activating a TGR5-cAMP-mTOR signal channel so as to play an anti-HBV role. The research finds that the improvement of the 5beta-CA level is expected to become a new thought for enhancing the NK cell function of a CHB patient, and a new technical means is provided for the treatment of CHB.

The invention provides a peripheral blood cell morphological analysis system and a heart failure degree judgment method, and the method comprises the steps: taking the peripheral blood cell morphological analysis system as the basis, obtaining the fluorescence signal, intensity, phase, bright field and dark field images of red blood cells, building the relation between the heart failure degree and red multi-dimensional features, and determining the heart failure degree of the red blood cells; and constructing, training and optimizing an erythrocyte morphological feature extraction network model based on machine learning. On the basis, a red blood cell characteristic image feature extraction network model with a fluorescence label is adopted to analyze a red blood cell image obtained by detecting a peripheral blood sample by a multi-parameter flow cytometry imaging system, the correlation between the characteristics of red blood cells in the peripheral blood sample and the heart failure degree is analyzed, and the heart failure degree is judged quickly and precisely.

The present application relates to the application of Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction, wherein the Bifidobacterium longum subsp.longum BL21 is a Bifidobacterium longum subsp.longum BL21 strain with a preservation number of CGMCC No.10452.The present application develops a new microbial strategy for improving hematopoietic dysfunction, and uses the Bifidobacterium longum subsp.longum BL21 in the preparation of a preparation for improving hematopoietic dysfunction.It is found that the Bifidobacterium longum subsp.longum BL21 can increase the number of peripheral blood cells (red blood cells and white blood cells), the content of platelets or the content of hemoglobin, reverse the weight loss caused by hematopoietic dysfunction, and improve the serum inflammatory response and the spleen inflammatory response caused by hematopoietic dysfunction.The present application also provides a new idea for the wide application of the Bifidobacterium longum subsp.longum BL21.

The invention relates to a human peripheral blood cell immunotyping antibody combination and method based on flow cytometry. The antibody combination comprises an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD8 antibody, an anti-EGFR antibody, an anti-CD25 antibody, an anti-CD127 antibody, an anti-CD45RA antibody, an anti-CCR7 antibody, an anti-CD27 antibody, an anti-PD-1 antibody, an antiTIGIT antibody and an anti-41BB antibody. The method comprises the following steps: mixing the antibody combination with a sample to be detected, incubating, performing flow cytometry detection to obtain detection data, and further judging the proportion and / or the number of target cell populations. According to the present invention, the optimal cell surface marker antibody combination is designed and obtained, the CAR-T cells in the sample are subjected to immune typing by using the 12-color antibody combination through the flow cytometry, the detection result is rapidly obtained, the CAR-T cell proportion of each phenotype is efficiently identified, and the method has high precision and high stability.

The invention provides a method for regulating and controlling proliferation and movement of human peripheral blood T cells by Amuc1100 protein. The method relates to the technologies of separation, activation and culture of human peripheral blood T cells, CCK-8 cell proliferation detection, Transwell cell chemotactic detection, flow cytometry receptor expression body detection and the like. The application of the Amuc1100 protein to treat T cells proves that the protein can significantly down-regulate the expression of CD25 and CXCR4 of the T cells and inhibit T cell proliferation and CXCL12 induced T cell chemotactic movement respectively. The method and research means for in-vitro regulation of T cell proliferation and chemotactic movement can be applied to targeted regulation of T cells and directional migration of intestinal tracts of the T cells, and are used for maintaining the steady state of the intestinal tracts, relieving intestinal inflammations and screening drugs to treat diseases related to the intestinal inflammations.

The invention belongs to the technical field of tumor immunotherapy, and relates to an anti-Claudin18.2 single-domain antibody, a multifunctional fusion protein, a recombinant natural killer cell (CT-CAR-NK), and preparation and application thereof. Through alpaca immunization and phage display library construction and panning, the single-domain antibody VHH-C18.2-1 specifically combined with Claudin18.2 is obtained, and the amino acid sequence of the single-domain antibody VHH-C18.2-1 is SEQ ID NO: 1. The amino acid sequence of the designed fusion protein is SEQ ID NO: 3, the fusion protein sequentially comprises a VHH-C18.2-1, a flexible Linker, a TGF-beta RII extracellular domain, a CD8alpha hinge region, a CD8alpha transmembrane region, a 4-1BB intracellular domain and a CD3zeta intracellular domain from the N end to the C end, and the fusion protein has the functions of targeting, resisting TGF-beta inhibition and activating signals. The fusion protein gene transfects human peripheral blood CD56 + CD3-NK cells through lentivirus to obtain CT-CAR-NK, in-vitro verification shows that the CT-CAR-NK still keeps efficient killing in an immunosuppression environment, tumor growth can be remarkably inhibited in vivo, the lifetime can be prolonged, and a safe and efficient scheme is provided for Claudin18.2 positive solid tumor treatment.

The invention relates to a quality control substance for flow cytometry HLA-B27 analysis as well as a preparation method and application of the quality control substance. The quality control substance comprises a negative quality control substance and a positive quality control substance; the negative quality control substance comprises human lymphocyte negative quality control substance simulation particles and human peripheral blood cells or simulation particles; an HLA-B27 antigen is not expressed on the surface of the human lymphocyte negative quality control substance mimic particle; the positive quality control substance comprises human lymphocyte positive quality control substance simulation particles and human peripheral blood cells or simulation particles; an HLA-B27 antigen is expressed on the surface of the human lymphocyte positive quality control substance simulation particle; cD3 antigens and CD45 antigens are expressed on the surfaces of the human lymphocyte positive quality control substance simulation particles and the human lymphocyte negative quality control substance simulation particles. The technical problem to be solved is how to provide a quality control substance which is good in stability and can be applied to flow cytometry HLA-B27 analysis.

Provided in the present invention is a grading method for evaluating the severity of the clinical symptoms of hypersplenism. In the present invention, a model for evaluating the severity of the clinical symptoms of hypersplenism is constructed by means of performing logistic regression analysis on PLT, WBC and RBC to establish a nomogram, converting regression coefficients into a visual scoring system, separately performing score assignment on the basis of primary and secondary factors, and finally constructing a total-score-based hypersplenism grading prediction model. The model in the present invention is used to evaluate the severity of the clinical symptoms of hypersplenism in patients. By means of correlation analysis of peripheral blood cell testing results of patients with hypersplenism, hypersplenism grades of the patients are evaluated, such that personalized treatment plans can be provided to the patients in a timely manner, thereby avoiding delays in treatment.

The application belongs to the technical field of bioinformatics analysis, and discloses a kind of anti-new coronavirus neutralizing antibody VJ gene preference analysis method, including antibody database acquisition data, data screening, selection frequency statistics, selection preference analysis, selection frequency and preference visualization, pairing frequency statistics, pairing preference analysis, pairing frequency and preference visualization.The beneficial aspects of the present application are that the neutralizing antibody and VJ selection and pairing frequency are tested by scientific statistical methods, and are visualized to make the result interpretation more simple and intuitive.Therefore, according to the above method, a new method for early prediction of anti-new coronavirus neutralizing antibody production based on peripheral blood B cell VJ gene frequency and preference is established, which can predict whether the probability of producing neutralizing antibody by the subject is higher than the baseline level of healthy people.

Compounds of the invention, such as compounds of formula (I):where R, R1, R2, R3, R4, R5, R6, and R7 are defined herein, are useful for treating cancer, autoimmune disorders, and / or skin dermatitis, and / or methods for increasing peripheral blood counts and / or improving immune system function. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

This useful solution, in the field of biotechnology and regenerative medicine, relates to a process for enhancing the efficiency of induced pluripotent stem cell (iPSC) colony formation from human peripheral blood mononuclear cells (PBMCs). The solution aims to overcome the low reprogramming efficiency, unstable colony formation, and limited iPSC cloning rates commonly encountered in PBMC iPSC generation processes. The technical essence of the solution lies in the synchronized optimization of the reprogramming process, including pre-activating PBMCs with an appropriate cytokine combination at predetermined times before reprogramming, using a non-integrated Sendai virus system under optimized transformation conditions, switching culture media at defined intervals to promote cell state transitions, and applying a selection, enrichment, and stabilization process for iPSC cloning in the initial passages after colony formation.The process also incorporates cell line quality control steps through assessment of residual Sendai virus RNA removal and mycoplasma contamination testing during line maintenance. Experimental results show that the proposed process increases the number of iPSC colonies formed, improves the rate of establishing stable iPSC lines, and enhances cell homogeneity and pluripotency maintenance. The solution can be applied in basic research, pathogenesis modeling, drug screening, regenerative medicine, and studies using induced pluripotent stem cells derived from human peripheral blood cells.

The invention provides a grading method for evaluating the clinical symptoms of hypersplenism, and the method comprises the steps: constructing a model for evaluating the clinical symptoms of hypersplenism, carrying out the Logistic regression analysis of the model through PLT, WBC and RBC, building a column diagram, converting a regression coefficient into a visual grading system, carrying out the score assignment according to primary and secondary factors, and carrying out the evaluation of the clinical symptoms of hypersplenism. And finally, constructing a splenohyperactivity grading prediction model according to the total score. The severity of the clinical symptom of the hypersplenidism of a patient is evaluated by adopting the model, the splenidism grading of the patient is evaluated by utilizing the correlation analysis of the peripheral blood cell detection result of the hypersplenidism patient, a personalized treatment scheme can be given to the patient in time, and the illness state is prevented from being delayed.

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating myelodysplastic syndrome and related complications thereof. The traditional Chinese medicine composition comprises sculellaria barbata, astragalus membranaceus, angelica sinensis, nightshade, radix curcumae, red ginseng, duchesnea indica, saussurea involucrata, cyclea verticillata and salvia miltiorrhiza. The traditional Chinese medicine composition has a good prevention and treatment effect on myelodysplastic syndrome and related complications thereof, can effectively inhibit proliferation of hematological tumor cells, and also can inhibit proliferation of the myelodysplastic syndrome by increasing the hemoglobin level, reducing the inflammatory cytokine level and reducing the proportion of peripheral blood T cells. Anemia, inflammation and low immune function caused by the myelodysplastic syndrome can be treated. The invention provides an effective strategy for prevention or treatment of myelodysplastic syndrome and related complications thereof, and provides a new direction for application of the traditional Chinese medicine composition.

The application provides a novel coronavirus specific T cell and a preparation method and application thereof, and belongs to the technical field of functional cells. The novel coronavirus specific T cell is enriched from peripheral blood PBMC cells, and after two rounds of in-vitro amplification, the novel coronavirus specific T cell with the order of 10 billion, an amplification multiple higher than 10,000 times and a purity higher than 90% is obtained, and the novel coronavirus specific T cell shows the characteristics of specific immune response to the novel coronavirus, thereby providing a new idea for preventing and treating the novel coronavirus pneumonia in clinic.

The application belongs to the technical field of biological medicine, and particularly relates to a TCR sequence targeting KRAS G12D antigen and application thereof. The CDR3 region of a wild type TCR is rationally designed and optimized through a simulation docking technology, and an optimized TCR with significantly improved affinity is obtained. Experimental results show that the TCR-T cell (human peripheral blood T cell TCR Homo sapiens) can effectively kill solid tumor cells, inhibit tumor growth in vivo and in vitro, improve the T cell immunotherapy effect, and can be used for preparing a cell drug for solid tumors, and has the advantages of high safety, strong targeting, significant effect and the like. The application provides a new drug selection and treatment scheme for the treatment of solid tumors.

The invention discloses an application of a Gal-9 + Th cell and / or Gal-9 + Treg as an AIH detection target spot. Researches find that compared with a healthy control group, the peripheral blood Gal-9 + Treg cell proportion and Gal-9 + Th cell proportion of an AIH patient baseline group are remarkably increased, and after ALT of a patient in a treatment group returns to normal, the Gal-9 + Treg cell proportion and the Gal-9 + Th cell proportion are both decreased compared with those before treatment, and it is indicated that the Gal-9 + Treg cell proportion and the Gal-9 + Th cell proportion are effective indexes for monitoring disease improvement. However, the AIH is a chronic disease process, even if the ALT level returns to normal, Gal-9 + Treg cells and Gal-9 + Th cells still do not return to the level of a healthy control group, the Gal-9 + Th cells are taken as detection targets, the progress of the AIH disease course can be monitored more accurately, and disease repetition and biochemical rebounding caused by premature drug withdrawal are prevented.

The invention belongs to the field of molecular targeted therapy, and discloses a small-molecule inhibitor CTPI3 of a targeted mitochondrial citric acid transporter SLC25A1 and application of the small-molecule inhibitor CTPI3 in tumor therapy. On the basis of an existing inhibitor CTPI2 structure, molecular design is carried out through an induced fit docking (IFD) module of Schrdinger software, and CTPI3 is obtained. Experiments show that the median inhibitory concentration (IC50) of CTPI3 on acute myelogenous leukemia (AML) cell lines (such as Kasumi-1 and THP1) and primary AML cells is obviously lower than that of CTPI2, the synergistic effect of CTPI3 and Venetoclax is enhanced, the mitochondrial ATP yield is reduced, and the TCA cycle metabolite level is affected. Animal experiments prove that CTPI3 can significantly prolong the lifetime of AML model mice and reduce leukemia load (spleen weight is reduced, and bone marrow and peripheral blood GFPcells are reduced), and has no significant toxicity (liver, kidney and brain histopathology is normal). The invention provides an efficient and safe new candidate drug for SLC25A1 targeted therapy.

The invention relates to the technical field of cell classification, in particular to a full-automatic classification detection method for peripheral blood cell morphology. The method comprises the following steps: acquiring a cell region in a cell display image of peripheral blood; obtaining an overlapped cell region according to the form of the cell region and the curvature of edge pixel points in the cell region; according to the length of each edge line in the overlapped cell area, the curvature of edge pixel points on each edge line and the curvature of intersection point pixel points of each edge line and other edge lines, obtaining exposed edge lines of the covered cells; and determining a complete cell edge line of the covered cell according to the curvature and the end point of the exposed edge line, and carrying out full-automatic classification detection on the peripheral blood cell morphology. By acquiring the complete cell edge line of the covered cell, the form of the covered cell is determined, the situation of inaccurate automatic identification and classification of the cell due to cell overlapping is avoided, and the accuracy of full-automatic classification detection of the form of the peripheral blood cell is improved.

The invention belongs to the technical field of thymus tissue slice ectopic transplantation, and particularly relates to a thymus tissue slice ectopic transplantation model and application thereof, and a construction method of the model comprises the following steps: S1, collecting thymus tissue from a donor mouse to prepare slices; s2, transferring the slices to a sterile mixed cellulose ester film in a tissue culture dish for culture; s3, forming a capsular bag at the transplantation part of the receptor mouse; s4, placing the cultured allogeneic thymus tissue slice in a bag, and sewing the bag; s5, feeding the mouse after the mouse recovers autonomous activity, performing ectopic transplantation on the thymus tissue slice cultured in vitro to the inguinal lymph node of the nude mouse, analyzing the regeneration condition of T cells in peripheral blood cells through flow cytometry, and performing histological detection on ectopic thymus to evaluate the immune function reconstruction effect. The traditional Chinese medicine composition reconstructs the body central immunity, and the effect is better than that of being transplanted to the kidney capsule part.